STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-08-16
Here’s whether Exelixis Inc (EXEL) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.06% over 10 days); RSI 39 — healthy momentum range; strong 1-year return of +33.2%; rising volume confirms the move (1.24x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative). Currently 11.0% off its 52-week high. Score: +5/7.
EXEL is holding above its long-term 200-day MA ($46.54) but has slipped below the 50-day MA ($54.14), pointing to short-term weakness in an otherwise intact trend. An RSI of 38.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +33.2% compares to +20.4% for SPY (beat the market by 12.8%).
$10,000 invested 1 year ago→ $13,319 today
vs. S&P 500 (SPY) — same period beat market by 12.8%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($46.54)
✗Above 50-day MA ($54.14)
✓RSI(14) neutral zone (30–70) — currently 38.6
✓Positive return (+33.2%)
!Within 10% of period high (−11.0%)
Period Range $51.24
$33.76$57.57
RSI (14) 38.6
0 · OversoldOverbought · 100
Key Metrics
Price$51.24
Period Return+33.2%
Period High$57.57
Period Low$33.76
Drawdown−11.0%
MA-50$54.14
MA-200$46.54
RSI (14)38.6
Avg Volume (30d)2.6M
vs. SPYbeat by 12.8%
Return Rank#389 of 1252
Trend Signals
Price is above the 200-day moving average ($46.54)